Endométriose et adénomyose

Just, Pierre‐Alexandre; Moret, Sandrine; Borghese, Bruno; Chapron, Charles

doi:10.1016/j.annpat.2021.03.012

Cited by 5 publications

(3 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adenomyosis and endometriosis have many difficult issues in common for diagnosis and treatment, both in terms of symptoms and fertility-related problems. As a result, a long period elapses between the onset of symptoms of the disease and the establishment of a final diagnosis for endometriosis, and for adenomyosis this period is expected to be even longer [12][13][14][15]. Both diseases have been found to negatively affect quality of life and lead to fatigue and depression [16,17].…”

Section: психосоматичний стан жінок репродуктивного віку з аденоміозо...mentioning

confidence: 99%

Psychosomatic status of women of reproductive age with adenomyosis

Azizova

2024

RHW

View full text Add to dashboard Cite

The objective: to study the impact of adenomyosis on the psychosomatic status of women of reproductive age.Materials and methods. A complex clinical-laboratory and instrumental prospective examination for women with adenomyosis was conducted in 224 patients aged 30 to 50 years (average age – 42.0±1.8 years). These patients were included in the main group of the study. The patients of the main group were divided into two subgroups depending on the form of adenomyosis: Group I – diffuse form – 106 women, Group II – nodular form – 118 women.The control group included 84 healthy women of reproductive age with a regular ovulatory menstrual cycle and no history of gynecological diseases.To assess the psychosomatic status of patients with adenomyosis we used the Aleksandrowicz method: a questionnaire of neurotic disorders – symptomatic (QND- S).Results. The conducted studies established that the largest number of patients were 36–40 years old – 92 (41.1±3.3%) women in the main group, and 37 (44.0±5.4%) women in the control group. A total of 152 (67.9±3.1%) patients of the main group were of reproductive age, 72 (32.1±3.1%) patients were of perimenopausal age.In patients with adenomyosis disorder of the menstrual cycle in the form of hyperpolymenorrhea was found in almost every third patient, and algomenorrhea – in almost every second person. The diagnosis was established for the first time in 8.49±2.7% of patients in Group I (9 women) and 3.38±1.8% in Group II (4 women).Less than 5 years of the disease was observed in 34.91±4.6% of patients of the Group I (37 women) and in 51.69±4.6% of the Group II (61 women). From 5 to 10 years, the disease was observed in 56.60±4.8% of patients of the Group I (60 women) and in 44.93±4.6% of the Group II (53 women). Affective stress (up to 15.50%), sleep disorders (up to 20.22%), anxiety-phobic disorders (up to 11.18%) were determined most often.Conclusions. In the vast majority of patients of reproductive age who have adenomyosis with pain syndrome, the personal characteristics are dominated by symptoms such as anxiety-phobic and depressive disorders, affective tension, sexual, obsessive and anankastic disorders.

show abstract

Section: психосоматичний стан жінок репродуктивного віку з аденоміозо...mentioning

confidence: 99%

Psychosomatic status of women of reproductive age with adenomyosis

Azizova

2024

RHW

View full text Add to dashboard Cite

show abstract

“…Adenomyosis is frequently associated with endometriosis [ 8 , 9 ]. While they share similarities, adenomyosis is considered a distinct entity from endometriosis, and there are clinical and pathological features that differentiate them [ 8 , 10 , 11 ]. Adenomyosis can also coexist with uterine leiomyomas [ 12 ] or congenital uterine anomalies [ 13 ], making their differentiation challenging on ultrasound examination [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Current Medical Therapy for Adenomyosis: From Bench to Bedside

Etrusco,

Barra,

Chiantera

et al. 2023

Drugs

View full text Add to dashboard Cite

Adenomyosis, characterized by the growth of endometrial tissue within the uterine wall, poses significant challenges in treatment. The literature primarily focuses on managing abnormal uterine bleeding (AUB) and dysmenorrhea, the main symptoms of adenomyosis. Nonsteroidal anti-inflammatory drugs (NSAIDs) and tranexamic acid provide limited support for mild symptoms or symptom re-exacerbation during hormone therapy. The levonorgestrel-releasing intrauterine system (LNG-IUS) is commonly employed in adenomyosis management, showing promise in symptom improvement and reducing uterine size, despite the lack of standardized guidelines. Dienogest (DNG) also exhibits potential benefits, but limited evidence hinders treatment recommendations. Danazol, while effective, is limited by androgenic side effects. Combined oral contraceptives (COCs) may be less effective than progestins but can be considered for contraception in young patients. Gonadotropin-releasing hormone (GnRH) agonists effectively manage symptoms but induce menopausal symptoms with prolonged use. GnRH antagonists are a recent option requiring further investigation. Aromatase inhibitors (AIs) show promise in alleviating AUB and pelvic pain, but their safety necessitates exploration and limited use within trials for refractory patients. This review highlights the complexity of diagnosing adenomyosis, its coexistence with endometriosis and uterine leiomyomas, and its impact on fertility and quality of life, complicating treatment decisions. It emphasizes the need for research on guidelines for medical management, fertility outcomes, long-term effects of therapies, and exploration of new investigational targets. Future research should optimize therapeutic strategies, expand our understanding of adenomyosis and its management, and establish evidence-based guidelines to improve patient outcomes and quality of life.

show abstract

“…Adenomyosis is a gynecological condition characterized by the presence of endometrial glands and stroma within the myometrial layer of the uterus ( 1 – 3 ). In the last decade, the advancements in imaging techniques have allowed us to detect adenomyosis in young fertile women as well.…”

Section: Introductionmentioning

confidence: 99%

SFRP4+IGFBP5hi NKT cells induced neural-like cell differentiation to contribute to adenomyosis pain

Chen

Zhu²,

Chen³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAdenomyosis is an estrogen-dependent gynecological disease. The pathogenesis of chronic pain, the main clinical symptom of adenomyosis, remains undefined. As a combination lymphocyte with both T-cell and natural killer (NK)–cell properties, NK T (NKT) cells play a role in immune defense against numerous diseases and modulate cell differentiation.MethodThis study analyzed the tissue-cell samples from adenomyosis with or without pain by single-cell sequencing.ResultWe found a specific population of secreted frizzled-related protein 4 (SFRP4)+NKT cells and a large amount of undifferentiated multipotent stem cells in the adenomyosis pain group. We discovered that a high expression of IGFBP5 in SFRP4+NKT cells could promote the differentiation of multipotent stem cells into neural-like cells via the single-cell trajectory. Through verification by the sample, we found that the degree of the expression of the neuronal marker NEFM was correlated with the duration of pain in adenomyosis patients. The expression of IGFBP5 was positively correlated with the pain scores of adenomyosis patients.ConclusionCollectively, these findings suggest that SFRP4+IGFBP5hi NKT cells were capable of converting part of the stem cells into neurogenic cells and inducing adenomyosis pain.

show abstract

Endométriose et adénomyose

Cited by 5 publications

References 65 publications

Psychosomatic status of women of reproductive age with adenomyosis

Psychosomatic status of women of reproductive age with adenomyosis

Current Medical Therapy for Adenomyosis: From Bench to Bedside

SFRP4+IGFBP5hi NKT cells induced neural-like cell differentiation to contribute to adenomyosis pain

Contact Info

Product

Resources

About